Company profile for GenSight Biologics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are an innovative clinical-stage gene therapy company currently focused on discovering, developing and commercializing novel therapies for patients with severe retinal neurodegenerative diseases.Our mission is to turn scientific advances in gene therapy into novel treatments for patients with severe degenerative diseases of the eye and the central nervous system. Our initial focus is on severe retinal diseases, with the goa...
We are an innovative clinical-stage gene therapy company currently focused on discovering, developing and commercializing novel therapies for patients with severe retinal neurodegenerative diseases.Our mission is to turn scientific advances in gene therapy into novel treatments for patients with severe degenerative diseases of the eye and the central nervous system. Our initial focus is on severe retinal diseases, with the goal of preserving or restoring vision in patients who suffer from sight-threatening ophthalmic diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
74, rue du Faubourg Saint-Antoine 75012 Paris
Telephone
Telephone
+33 1 76 21 72 20
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

Global ChemShow

Not Confirmed

envelop Contact Supplier

Global ChemShow

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251029196714/en/GenSight-Biologics-Announces-Regulatory-Authorizations-for-Individual-Patient-Expanded-Access-Treatment-with-GS010LUMEVOQ-in-the-US

BUSINESSWIRE
30 Oct 2025

https://www.businesswire.com/news/home/20251007011599/en/GenSight-Biologics-Reports-Cash-Position-as-of-September-30-2025

BUSINESSWIRE
07 Oct 2025

https://www.businesswire.com/news/home/20250929800692/en/GenSight-Biologics-Reports-Interim-Financial-Results-for-the-First-Half-of-2025

BUSINESSWIRE
29 Sep 2025

https://www.businesswire.com/news/home/20250828662965/en/GenSight-Biologics-Postpones-Release-of-2025-Half-Year-Financial-Results

BUSINESSWIRE
28 Aug 2025

https://www.businesswire.com/news/home/20250717701196/en/GenSight-Biologics-Announces-Publication-on-Predictors-of-Final-Visual-Outcome-in-Patients-Treated-with-LUMEVOQ-Gene-Therapy

BUSINESSWIRE
17 Jul 2025

https://www.businesswire.com/news/home/20250708615591/en/GenSight-Biologics-Reports-Cash-Position-as-of-June-30-2025

BUSINESSWIRE
08 Jul 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty